2024 · Journal of pharmaceutical and biomedical analysis · paywalled
Development and validation of a UPLC-PDA method for quantifying ceftazidime in dried blood spots
Lv et al.
The finding, in our words
The authors validated a UPLC-PDA assay for ceftazidime in 10 microlitre dried blood spots collected with the Capitainer device from neonatal patients, achieving accuracy of 90.1 to 104.8 per cent and precision within 11.7 per cent coefficient of variation across a quantification range of 0.5 to 200 micrograms per millilitre, and confirmed the method worked on clinical neonatal samples. This supports microsampling-based therapeutic drug monitoring of an antimicrobial in a vulnerable population where conventional venous blood draws are difficult.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
A validated high-throughput LC-MS/MS assay for piperaquine from dried blood spots achieved 54-72% recovery with <9% relative standard deviation and a quantification limit of 3 ng/mL, enabling detection for 4-8 weeks post-dose. The method showed minimal haematocrit interference and is suitable for therapeutic drug monitoring of antimalarial treatment in resource-limited settings and pediatric populations.
The validated LC-MS/MS method showed similar pharmacokinetic profiles for albendazole and its metabolites across plasma, whole blood, dried blood spots and Mitra microsamples from hookworm-infected adolescents, supporting microsampling for paediatric pharmacokinetic studies. Mitra extraction proved more robust than dried blood spots during validation and is recommended for future albendazole pharmacokinetic work, despite higher albendazole sulfone concentrations observed in both microsampling devices compared with wet matrices.
The study developed and validated a rapid LC-MS/MS method for quantifying cefazolin in capillary whole blood collected via VAMS, plasma, and plasma ultrafiltrate, showing robust performance across matrices and successful application in a pediatric pilot cohort for therapeutic drug monitoring.
A systematic review found mixed economic evidence for microsampling in therapeutic drug monitoring; one study reported no cost reduction with DBS home-sampling, €688 versus €676, whilst another predicted savings up to 61%. The authors caution that more work is required to assess costs alongside clinical outcomes and optimise logistics for decentralised implementation.
The study compared quantitative dried blood spot (qDBS) and volumetric absorptive microsampling (VAMS) devices for measuring ganciclovir levels in capillary blood from pediatric renal transplant recipients. This comparison provides evidence for choosing between microsampling devices in therapeutic drug monitoring, supporting decentralised sampling approaches that reduce patient burden while maintaining analytical accuracy.